Omnicell, Inc. (NASDAQ:OMCL) Shares Sold by Advantage Alpha Capital Partners LP

Advantage Alpha Capital Partners LP lowered its position in Omnicell, Inc. (NASDAQ:OMCL) by 35.1% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 45,288 shares of the company’s stock after selling 24,485 shares during the quarter. Advantage Alpha Capital Partners LP’s holdings in Omnicell were worth $1,975,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in OMCL. Victory Capital Management Inc. increased its position in shares of Omnicell by 11,982.3% during the third quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock worth $50,071,000 after acquiring an additional 1,138,921 shares during the last quarter. Federated Hermes Inc. grew its stake in Omnicell by 1,113.6% during the 2nd quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock valued at $26,830,000 after purchasing an additional 909,480 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. purchased a new stake in Omnicell during the 3rd quarter worth approximately $32,721,000. Pacer Advisors Inc. raised its position in shares of Omnicell by 32.6% in the 2nd quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock valued at $56,047,000 after purchasing an additional 508,789 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Omnicell by 750.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company’s stock valued at $12,820,000 after buying an additional 259,463 shares during the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

OMCL has been the subject of a number of research analyst reports. Bank of America restated a “neutral” rating and issued a $57.00 price target (up previously from $44.00) on shares of Omnicell in a research note on Thursday, October 31st. StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Benchmark reaffirmed a “buy” rating and set a $48.00 price target on shares of Omnicell in a research report on Wednesday, October 9th. JPMorgan Chase & Co. boosted their price objective on Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Finally, Barclays increased their target price on Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Omnicell presently has a consensus rating of “Hold” and an average target price of $52.00.

Omnicell Stock Up 0.6 %

OMCL opened at $45.96 on Tuesday. The company’s 50-day moving average price is $44.29 and its 200 day moving average price is $37.57. Omnicell, Inc. has a fifty-two week low of $25.12 and a fifty-two week high of $55.74. The firm has a market cap of $2.13 billion, a price-to-earnings ratio of -117.85, a price-to-earnings-growth ratio of 38.42 and a beta of 0.81.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.